Spyre Therapeutics Inc. (NASDAQ: SYRE)
$27.5550
-0.1450 ( -2.50% ) 188.9K
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. A range of pharmaceutical options to address IBD exists, including anti-inflammatory drugs, immunosuppressants, and biologics.
Market Data
Open
$27.5550
Previous close
$27.7000
Volume
188.9K
Market cap
N/A
Day range
$27.3310 - $31.4000
52 week range
$10.4200 - $47.9700
SEC Filings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 16 | Nov 19, 2024 |
10-q/a | Quarterly Reports | 74 | Nov 18, 2024 |
10-k/a | Quarterly Reports | 108 | Nov 18, 2024 |
10-q/a | Quarterly Reports | 68 | Nov 18, 2024 |
8-k | 8K-related | 13 | Nov 18, 2024 |
10-q/a | Quarterly Reports | 77 | Nov 18, 2024 |
8-k | 8K-related | 47 | Nov 12, 2024 |
4 | Insider transactions | 1 | Nov 08, 2024 |
8-k | 8K-related | 15 | Nov 07, 2024 |
10-q | Quarterly Reports | 88 | Nov 07, 2024 |